Review





Similar Products

90
Qiagen qproteome plasma membrane protein kit #37601
Qproteome Plasma Membrane Protein Kit #37601, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/qproteome plasma membrane protein kit #37601/product/Qiagen
Average 90 stars, based on 1 article reviews
qproteome plasma membrane protein kit #37601 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology ctla 4
Ctla 4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ctla 4/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
ctla 4 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

90
Medtronic inc implantable programmable neurostimulators (activa™ pc 37601 or activa™ rc 37612
Implantable Programmable Neurostimulators (Activa™ Pc 37601 Or Activa™ Rc 37612, supplied by Medtronic inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/implantable programmable neurostimulators (activa™ pc 37601 or activa™ rc 37612/product/Medtronic inc
Average 90 stars, based on 1 article reviews
implantable programmable neurostimulators (activa™ pc 37601 or activa™ rc 37612 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Medtronic inc activa pc/rc device (model 37601/37612)
Activa Pc/Rc Device (Model 37601/37612), supplied by Medtronic inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/activa pc/rc device (model 37601/37612)/product/Medtronic inc
Average 90 stars, based on 1 article reviews
activa pc/rc device (model 37601/37612) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Addgene inc e6ap expression plasmid pcmvt n ha he6ap
HBx stabilizes HCV core protein by protecting it from ubiquitin-dependent proteasomal degradation. (A) HepG2 cells were transfected with HA-Core with or without HA-HBx for 48 h, treated with 50 μM cycloheximide (CHX) for the indicated times, and collected for Western blotting. The band intensity of HA-Core was quantified as described in the legend of <xref ref-type=Fig. 1A to determine the half-life ( t 1/2 ) of the HCV core protein ( n = 4). (B) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV at an MOI of 10 for an additional 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (C) Huh7D-NTCP cells were coinfected with HBV at an MOI of 30 and HCV at an MOI of 10 for 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (D) HepG2 cells were transfected with HA-HBx, HA-Core, an E6AP expression plasmid, and HA-ubiquitin (HA-Ub) for 48 h. Total HA-Core proteins were immunoprecipitated with an anti-HCV core protein antibody and subjected to Western blotting using an anti-HA antibody to detect polyubiquitinated HA-Core. The input shows the levels of the indicated proteins in whole-cell lysates. (E) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, scrambled (SC) shRNA, and E6AP shRNA for 48 h, and samples were collected for immunoprecipitation (IP), as described above for panel D. (F) Huh7D-NTCP cells were transfected with an empty vector, an E6AP expression plasmid, and HA-Ub for 24 h and then monoinfected with HCV or coinfected with HBV and HCV for 48 h as described above for panel C, and samples were collected for IP as described above for panel D. (G) Huh7D cells were transfected with an empty vector, the 1.2-mer WT replicon, an E6AP expression plasmid, and HA-Ub for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (H) HepG2 cells were transfected with either HA-HBx or HA-Core, followed by Western blot analysis. (I) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, and an E6AP expression plasmid for 48 h. (J) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (K) Huh7D-NTCP cells were transfected with either an empty vector or an E6AP expression plasmid for 24 h and then either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for an additional 48 h. (L) HepG2 cells were transfected with the indicated amounts of HA-HBx and HA-Core for 44 h and then either mock treated or treated with 10 μM MG132 for an additional 4 h. (M) HepG2 cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel J. For lanes 4 to 6, cells were either mock treated or treated with 10 μM MG132 for 4 h before harvest. " width="250" height="auto" />
E6ap Expression Plasmid Pcmvt N Ha He6ap, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e6ap expression plasmid pcmvt n ha he6ap/product/Addgene inc
Average 90 stars, based on 1 article reviews
e6ap expression plasmid pcmvt n ha he6ap - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology 376016 rrid ab 10988256
HBx stabilizes HCV core protein by protecting it from ubiquitin-dependent proteasomal degradation. (A) HepG2 cells were transfected with HA-Core with or without HA-HBx for 48 h, treated with 50 μM cycloheximide (CHX) for the indicated times, and collected for Western blotting. The band intensity of HA-Core was quantified as described in the legend of <xref ref-type=Fig. 1A to determine the half-life ( t 1/2 ) of the HCV core protein ( n = 4). (B) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV at an MOI of 10 for an additional 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (C) Huh7D-NTCP cells were coinfected with HBV at an MOI of 30 and HCV at an MOI of 10 for 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (D) HepG2 cells were transfected with HA-HBx, HA-Core, an E6AP expression plasmid, and HA-ubiquitin (HA-Ub) for 48 h. Total HA-Core proteins were immunoprecipitated with an anti-HCV core protein antibody and subjected to Western blotting using an anti-HA antibody to detect polyubiquitinated HA-Core. The input shows the levels of the indicated proteins in whole-cell lysates. (E) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, scrambled (SC) shRNA, and E6AP shRNA for 48 h, and samples were collected for immunoprecipitation (IP), as described above for panel D. (F) Huh7D-NTCP cells were transfected with an empty vector, an E6AP expression plasmid, and HA-Ub for 24 h and then monoinfected with HCV or coinfected with HBV and HCV for 48 h as described above for panel C, and samples were collected for IP as described above for panel D. (G) Huh7D cells were transfected with an empty vector, the 1.2-mer WT replicon, an E6AP expression plasmid, and HA-Ub for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (H) HepG2 cells were transfected with either HA-HBx or HA-Core, followed by Western blot analysis. (I) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, and an E6AP expression plasmid for 48 h. (J) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (K) Huh7D-NTCP cells were transfected with either an empty vector or an E6AP expression plasmid for 24 h and then either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for an additional 48 h. (L) HepG2 cells were transfected with the indicated amounts of HA-HBx and HA-Core for 44 h and then either mock treated or treated with 10 μM MG132 for an additional 4 h. (M) HepG2 cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel J. For lanes 4 to 6, cells were either mock treated or treated with 10 μM MG132 for 4 h before harvest. " width="250" height="auto" />
376016 Rrid Ab 10988256, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/376016 rrid ab 10988256/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
376016 rrid ab 10988256 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

90
Addgene inc e6ap wt
HBx stabilizes HCV core protein by protecting it from ubiquitin-dependent proteasomal degradation. (A) HepG2 cells were transfected with HA-Core with or without HA-HBx for 48 h, treated with 50 μM cycloheximide (CHX) for the indicated times, and collected for Western blotting. The band intensity of HA-Core was quantified as described in the legend of <xref ref-type=Fig. 1A to determine the half-life ( t 1/2 ) of the HCV core protein ( n = 4). (B) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV at an MOI of 10 for an additional 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (C) Huh7D-NTCP cells were coinfected with HBV at an MOI of 30 and HCV at an MOI of 10 for 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (D) HepG2 cells were transfected with HA-HBx, HA-Core, an E6AP expression plasmid, and HA-ubiquitin (HA-Ub) for 48 h. Total HA-Core proteins were immunoprecipitated with an anti-HCV core protein antibody and subjected to Western blotting using an anti-HA antibody to detect polyubiquitinated HA-Core. The input shows the levels of the indicated proteins in whole-cell lysates. (E) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, scrambled (SC) shRNA, and E6AP shRNA for 48 h, and samples were collected for immunoprecipitation (IP), as described above for panel D. (F) Huh7D-NTCP cells were transfected with an empty vector, an E6AP expression plasmid, and HA-Ub for 24 h and then monoinfected with HCV or coinfected with HBV and HCV for 48 h as described above for panel C, and samples were collected for IP as described above for panel D. (G) Huh7D cells were transfected with an empty vector, the 1.2-mer WT replicon, an E6AP expression plasmid, and HA-Ub for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (H) HepG2 cells were transfected with either HA-HBx or HA-Core, followed by Western blot analysis. (I) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, and an E6AP expression plasmid for 48 h. (J) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (K) Huh7D-NTCP cells were transfected with either an empty vector or an E6AP expression plasmid for 24 h and then either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for an additional 48 h. (L) HepG2 cells were transfected with the indicated amounts of HA-HBx and HA-Core for 44 h and then either mock treated or treated with 10 μM MG132 for an additional 4 h. (M) HepG2 cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel J. For lanes 4 to 6, cells were either mock treated or treated with 10 μM MG132 for 4 h before harvest. " width="250" height="auto" />
E6ap Wt, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e6ap wt/product/Addgene inc
Average 90 stars, based on 1 article reviews
e6ap wt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology sc 376016
HBx stabilizes HCV core protein by protecting it from ubiquitin-dependent proteasomal degradation. (A) HepG2 cells were transfected with HA-Core with or without HA-HBx for 48 h, treated with 50 μM cycloheximide (CHX) for the indicated times, and collected for Western blotting. The band intensity of HA-Core was quantified as described in the legend of <xref ref-type=Fig. 1A to determine the half-life ( t 1/2 ) of the HCV core protein ( n = 4). (B) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV at an MOI of 10 for an additional 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (C) Huh7D-NTCP cells were coinfected with HBV at an MOI of 30 and HCV at an MOI of 10 for 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (D) HepG2 cells were transfected with HA-HBx, HA-Core, an E6AP expression plasmid, and HA-ubiquitin (HA-Ub) for 48 h. Total HA-Core proteins were immunoprecipitated with an anti-HCV core protein antibody and subjected to Western blotting using an anti-HA antibody to detect polyubiquitinated HA-Core. The input shows the levels of the indicated proteins in whole-cell lysates. (E) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, scrambled (SC) shRNA, and E6AP shRNA for 48 h, and samples were collected for immunoprecipitation (IP), as described above for panel D. (F) Huh7D-NTCP cells were transfected with an empty vector, an E6AP expression plasmid, and HA-Ub for 24 h and then monoinfected with HCV or coinfected with HBV and HCV for 48 h as described above for panel C, and samples were collected for IP as described above for panel D. (G) Huh7D cells were transfected with an empty vector, the 1.2-mer WT replicon, an E6AP expression plasmid, and HA-Ub for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (H) HepG2 cells were transfected with either HA-HBx or HA-Core, followed by Western blot analysis. (I) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, and an E6AP expression plasmid for 48 h. (J) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (K) Huh7D-NTCP cells were transfected with either an empty vector or an E6AP expression plasmid for 24 h and then either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for an additional 48 h. (L) HepG2 cells were transfected with the indicated amounts of HA-HBx and HA-Core for 44 h and then either mock treated or treated with 10 μM MG132 for an additional 4 h. (M) HepG2 cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel J. For lanes 4 to 6, cells were either mock treated or treated with 10 μM MG132 for 4 h before harvest. " width="250" height="auto" />
Sc 376016, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sc 376016/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
sc 376016 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology sc 376012
HBx stabilizes HCV core protein by protecting it from ubiquitin-dependent proteasomal degradation. (A) HepG2 cells were transfected with HA-Core with or without HA-HBx for 48 h, treated with 50 μM cycloheximide (CHX) for the indicated times, and collected for Western blotting. The band intensity of HA-Core was quantified as described in the legend of <xref ref-type=Fig. 1A to determine the half-life ( t 1/2 ) of the HCV core protein ( n = 4). (B) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV at an MOI of 10 for an additional 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (C) Huh7D-NTCP cells were coinfected with HBV at an MOI of 30 and HCV at an MOI of 10 for 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (D) HepG2 cells were transfected with HA-HBx, HA-Core, an E6AP expression plasmid, and HA-ubiquitin (HA-Ub) for 48 h. Total HA-Core proteins were immunoprecipitated with an anti-HCV core protein antibody and subjected to Western blotting using an anti-HA antibody to detect polyubiquitinated HA-Core. The input shows the levels of the indicated proteins in whole-cell lysates. (E) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, scrambled (SC) shRNA, and E6AP shRNA for 48 h, and samples were collected for immunoprecipitation (IP), as described above for panel D. (F) Huh7D-NTCP cells were transfected with an empty vector, an E6AP expression plasmid, and HA-Ub for 24 h and then monoinfected with HCV or coinfected with HBV and HCV for 48 h as described above for panel C, and samples were collected for IP as described above for panel D. (G) Huh7D cells were transfected with an empty vector, the 1.2-mer WT replicon, an E6AP expression plasmid, and HA-Ub for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (H) HepG2 cells were transfected with either HA-HBx or HA-Core, followed by Western blot analysis. (I) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, and an E6AP expression plasmid for 48 h. (J) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (K) Huh7D-NTCP cells were transfected with either an empty vector or an E6AP expression plasmid for 24 h and then either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for an additional 48 h. (L) HepG2 cells were transfected with the indicated amounts of HA-HBx and HA-Core for 44 h and then either mock treated or treated with 10 μM MG132 for an additional 4 h. (M) HepG2 cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel J. For lanes 4 to 6, cells were either mock treated or treated with 10 μM MG132 for 4 h before harvest. " width="250" height="auto" />
Sc 376012, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sc 376012/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
sc 376012 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology mouse anti cd80
HBx stabilizes HCV core protein by protecting it from ubiquitin-dependent proteasomal degradation. (A) HepG2 cells were transfected with HA-Core with or without HA-HBx for 48 h, treated with 50 μM cycloheximide (CHX) for the indicated times, and collected for Western blotting. The band intensity of HA-Core was quantified as described in the legend of <xref ref-type=Fig. 1A to determine the half-life ( t 1/2 ) of the HCV core protein ( n = 4). (B) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV at an MOI of 10 for an additional 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (C) Huh7D-NTCP cells were coinfected with HBV at an MOI of 30 and HCV at an MOI of 10 for 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (D) HepG2 cells were transfected with HA-HBx, HA-Core, an E6AP expression plasmid, and HA-ubiquitin (HA-Ub) for 48 h. Total HA-Core proteins were immunoprecipitated with an anti-HCV core protein antibody and subjected to Western blotting using an anti-HA antibody to detect polyubiquitinated HA-Core. The input shows the levels of the indicated proteins in whole-cell lysates. (E) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, scrambled (SC) shRNA, and E6AP shRNA for 48 h, and samples were collected for immunoprecipitation (IP), as described above for panel D. (F) Huh7D-NTCP cells were transfected with an empty vector, an E6AP expression plasmid, and HA-Ub for 24 h and then monoinfected with HCV or coinfected with HBV and HCV for 48 h as described above for panel C, and samples were collected for IP as described above for panel D. (G) Huh7D cells were transfected with an empty vector, the 1.2-mer WT replicon, an E6AP expression plasmid, and HA-Ub for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (H) HepG2 cells were transfected with either HA-HBx or HA-Core, followed by Western blot analysis. (I) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, and an E6AP expression plasmid for 48 h. (J) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (K) Huh7D-NTCP cells were transfected with either an empty vector or an E6AP expression plasmid for 24 h and then either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for an additional 48 h. (L) HepG2 cells were transfected with the indicated amounts of HA-HBx and HA-Core for 44 h and then either mock treated or treated with 10 μM MG132 for an additional 4 h. (M) HepG2 cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel J. For lanes 4 to 6, cells were either mock treated or treated with 10 μM MG132 for 4 h before harvest. " width="250" height="auto" />
Mouse Anti Cd80, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti cd80/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
mouse anti cd80 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

Image Search Results


HBx stabilizes HCV core protein by protecting it from ubiquitin-dependent proteasomal degradation. (A) HepG2 cells were transfected with HA-Core with or without HA-HBx for 48 h, treated with 50 μM cycloheximide (CHX) for the indicated times, and collected for Western blotting. The band intensity of HA-Core was quantified as described in the legend of <xref ref-type=Fig. 1A to determine the half-life ( t 1/2 ) of the HCV core protein ( n = 4). (B) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV at an MOI of 10 for an additional 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (C) Huh7D-NTCP cells were coinfected with HBV at an MOI of 30 and HCV at an MOI of 10 for 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (D) HepG2 cells were transfected with HA-HBx, HA-Core, an E6AP expression plasmid, and HA-ubiquitin (HA-Ub) for 48 h. Total HA-Core proteins were immunoprecipitated with an anti-HCV core protein antibody and subjected to Western blotting using an anti-HA antibody to detect polyubiquitinated HA-Core. The input shows the levels of the indicated proteins in whole-cell lysates. (E) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, scrambled (SC) shRNA, and E6AP shRNA for 48 h, and samples were collected for immunoprecipitation (IP), as described above for panel D. (F) Huh7D-NTCP cells were transfected with an empty vector, an E6AP expression plasmid, and HA-Ub for 24 h and then monoinfected with HCV or coinfected with HBV and HCV for 48 h as described above for panel C, and samples were collected for IP as described above for panel D. (G) Huh7D cells were transfected with an empty vector, the 1.2-mer WT replicon, an E6AP expression plasmid, and HA-Ub for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (H) HepG2 cells were transfected with either HA-HBx or HA-Core, followed by Western blot analysis. (I) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, and an E6AP expression plasmid for 48 h. (J) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (K) Huh7D-NTCP cells were transfected with either an empty vector or an E6AP expression plasmid for 24 h and then either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for an additional 48 h. (L) HepG2 cells were transfected with the indicated amounts of HA-HBx and HA-Core for 44 h and then either mock treated or treated with 10 μM MG132 for an additional 4 h. (M) HepG2 cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel J. For lanes 4 to 6, cells were either mock treated or treated with 10 μM MG132 for 4 h before harvest. " width="100%" height="100%">

Journal: Microbiology Spectrum

Article Title: Hepatitis B Virus X Protein Stimulates Hepatitis C Virus (HCV) Replication by Protecting HCV Core Protein from E6AP-Mediated Proteasomal Degradation

doi: 10.1128/spectrum.01432-22

Figure Lengend Snippet: HBx stabilizes HCV core protein by protecting it from ubiquitin-dependent proteasomal degradation. (A) HepG2 cells were transfected with HA-Core with or without HA-HBx for 48 h, treated with 50 μM cycloheximide (CHX) for the indicated times, and collected for Western blotting. The band intensity of HA-Core was quantified as described in the legend of Fig. 1A to determine the half-life ( t 1/2 ) of the HCV core protein ( n = 4). (B) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV at an MOI of 10 for an additional 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (C) Huh7D-NTCP cells were coinfected with HBV at an MOI of 30 and HCV at an MOI of 10 for 48 h. The t 1/2 value of the HCV core protein was determined as described above for panel A. (D) HepG2 cells were transfected with HA-HBx, HA-Core, an E6AP expression plasmid, and HA-ubiquitin (HA-Ub) for 48 h. Total HA-Core proteins were immunoprecipitated with an anti-HCV core protein antibody and subjected to Western blotting using an anti-HA antibody to detect polyubiquitinated HA-Core. The input shows the levels of the indicated proteins in whole-cell lysates. (E) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, scrambled (SC) shRNA, and E6AP shRNA for 48 h, and samples were collected for immunoprecipitation (IP), as described above for panel D. (F) Huh7D-NTCP cells were transfected with an empty vector, an E6AP expression plasmid, and HA-Ub for 24 h and then monoinfected with HCV or coinfected with HBV and HCV for 48 h as described above for panel C, and samples were collected for IP as described above for panel D. (G) Huh7D cells were transfected with an empty vector, the 1.2-mer WT replicon, an E6AP expression plasmid, and HA-Ub for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (H) HepG2 cells were transfected with either HA-HBx or HA-Core, followed by Western blot analysis. (I) HepG2 cells were transfected with the indicated amounts of HA-HBx, HA-Core, and an E6AP expression plasmid for 48 h. (J) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. (K) Huh7D-NTCP cells were transfected with either an empty vector or an E6AP expression plasmid for 24 h and then either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for an additional 48 h. (L) HepG2 cells were transfected with the indicated amounts of HA-HBx and HA-Core for 44 h and then either mock treated or treated with 10 μM MG132 for an additional 4 h. (M) HepG2 cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel J. For lanes 4 to 6, cells were either mock treated or treated with 10 μM MG132 for 4 h before harvest.

Article Snippet: The E6AP expression plasmid pCMVT N-HA-hE6AP (catalog no. 37601), encoding full-length human HA-tagged E6AP, was purchased from Addgene.

Techniques: Ubiquitin Proteomics, Transfection, Western Blot, Infection, Expressing, Plasmid Preparation, Immunoprecipitation, shRNA

HBx upregulates HCV core protein levels by repressing E6AP expression via DNA methylation. (A) HepG2 cells were transfected with the indicated amounts of HA-Core and HA-HBx for 48 h. DNA methyltransferase (DNMT) activity in the cell extracts was determined ( n = 6). The levels of the indicated proteins were determined by Western blotting. (B) Methylation-specific PCR (MSP) was performed to determine whether the CpG sites within the E6AP promoter were unmethylated (U) or methylated (M) in cells prepared as described above for panel A. (C) Huh7D cells were transfected with the 1.2-mer WT replicon for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. DNMT activity in the cell extracts was determined ( n = 4). The levels of the indicated proteins were determined by Western blotting. (D) MSP was performed as described above for panel B with cells prepared as described above for panel C. (E) Huh7D-NTCP cells were either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for 48 h. The DNMT activity in the cell extracts was determined ( n = 4). (F) MSP was performed as described above for panel B with cells prepared as described above for panel E. (G) HepG2 cells were transfected with the indicated amounts of HA-Core and HA-HBx for 48 h. For lanes 4 to 6, cells were treated with 10 μM 5-aza-2′dC for 24 h before harvest. (H) HepG2 cells were transfected with the indicated amounts of HA-Core and HA-HBx in the presence and absence of the DNMT1 shRNA plasmid for 48 h. OD 450 , optical density at 450 nm.

Journal: Microbiology Spectrum

Article Title: Hepatitis B Virus X Protein Stimulates Hepatitis C Virus (HCV) Replication by Protecting HCV Core Protein from E6AP-Mediated Proteasomal Degradation

doi: 10.1128/spectrum.01432-22

Figure Lengend Snippet: HBx upregulates HCV core protein levels by repressing E6AP expression via DNA methylation. (A) HepG2 cells were transfected with the indicated amounts of HA-Core and HA-HBx for 48 h. DNA methyltransferase (DNMT) activity in the cell extracts was determined ( n = 6). The levels of the indicated proteins were determined by Western blotting. (B) Methylation-specific PCR (MSP) was performed to determine whether the CpG sites within the E6AP promoter were unmethylated (U) or methylated (M) in cells prepared as described above for panel A. (C) Huh7D cells were transfected with the 1.2-mer WT replicon for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h. DNMT activity in the cell extracts was determined ( n = 4). The levels of the indicated proteins were determined by Western blotting. (D) MSP was performed as described above for panel B with cells prepared as described above for panel C. (E) Huh7D-NTCP cells were either mock infected or infected with HBV at an MOI of 30 and/or HCV at an MOI of 10 for 48 h. The DNMT activity in the cell extracts was determined ( n = 4). (F) MSP was performed as described above for panel B with cells prepared as described above for panel E. (G) HepG2 cells were transfected with the indicated amounts of HA-Core and HA-HBx for 48 h. For lanes 4 to 6, cells were treated with 10 μM 5-aza-2′dC for 24 h before harvest. (H) HepG2 cells were transfected with the indicated amounts of HA-Core and HA-HBx in the presence and absence of the DNMT1 shRNA plasmid for 48 h. OD 450 , optical density at 450 nm.

Article Snippet: The E6AP expression plasmid pCMVT N-HA-hE6AP (catalog no. 37601), encoding full-length human HA-tagged E6AP, was purchased from Addgene.

Techniques: Expressing, DNA Methylation Assay, Transfection, Activity Assay, Western Blot, Methylation, Infection, shRNA, Plasmid Preparation

HBx stimulates HCV replication by repressing E6AP expression via DNA methylation. (A) Huh7D cells were transfected with HA-HBx and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h, followed by Western blotting. (B) Levels of extracellular HCV particles from Huh7D cells prepared as described above for panel A were measured by qRT-PCR as described in the legend of <xref ref-type=Fig. 1B ( n = 4). (C) Huh7D cells were transfected with HA-HBx and then infected with HCV as described above for panel A, in the presence or absence of 10 μM 5-aza-2′dC. (D) Levels of extracellular HCV RNA from Huh7D cells prepared as described above for panel C were measured as described in the legend of Fig. 1B ( n = 5). (E) Huh7D cells were transfected with HA-HBx and a DNMT1 shRNA plasmid and then infected with HCV as described above for panel A, followed by Western blotting. (F) Levels of extracellular HCV RNA from Huh7D cells prepared as described above for panel E were measured as described in the legend of Fig. 1B ( n = 5). (G) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid and then infected with HCV as described above for panel A. (H) Levels of extracellular HCV RNA from cells prepared as described above for panel G were measured as described in the legend of Fig. 1B ( n = 3). (I) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel A. For lanes 4 and 5, cells were treated with 10 μM 5-aza-2′dC, as described in the legend of Fig. 4G . (J) Levels of extracellular HCV RNA from cells prepared as described above for panel I were measured as described in the legend of Fig. 1B ( n = 5). (K) Huh7D cells were transfected with the 1.2-mer WT replicon and a DNMT shRNA plasmid and then infected with HCV as described above for panel A. (L) Levels of extracellular HCV RNA from cells prepared as described above for panel K were measured as described in the legend of Fig. 1B ( n = 5). (M) Huh7D cells were transfected with HA-HBx and an E6AP shRNA plasmid and then infected with HCV as described above for panel A, followed by Western blotting. (N) Levels of extracellular HCV RNA from Huh7D cells prepared as described above for panel M were measured as described in the legend of Fig. 1B ( n = 5). (O) Huh7D cells were transfected with the 1.2-mer WT replicon and E6AP shRNA and then infected with HCV as described above for panel A. (P) Levels of extracellular HCV RNA from cells prepared as described above for panel O were measured as described in the legend of Fig. 1B ( n = 5). " width="100%" height="100%">

Journal: Microbiology Spectrum

Article Title: Hepatitis B Virus X Protein Stimulates Hepatitis C Virus (HCV) Replication by Protecting HCV Core Protein from E6AP-Mediated Proteasomal Degradation

doi: 10.1128/spectrum.01432-22

Figure Lengend Snippet: HBx stimulates HCV replication by repressing E6AP expression via DNA methylation. (A) Huh7D cells were transfected with HA-HBx and an E6AP expression plasmid for 24 h and then infected with HCV at an MOI of 10 for an additional 48 h, followed by Western blotting. (B) Levels of extracellular HCV particles from Huh7D cells prepared as described above for panel A were measured by qRT-PCR as described in the legend of Fig. 1B ( n = 4). (C) Huh7D cells were transfected with HA-HBx and then infected with HCV as described above for panel A, in the presence or absence of 10 μM 5-aza-2′dC. (D) Levels of extracellular HCV RNA from Huh7D cells prepared as described above for panel C were measured as described in the legend of Fig. 1B ( n = 5). (E) Huh7D cells were transfected with HA-HBx and a DNMT1 shRNA plasmid and then infected with HCV as described above for panel A, followed by Western blotting. (F) Levels of extracellular HCV RNA from Huh7D cells prepared as described above for panel E were measured as described in the legend of Fig. 1B ( n = 5). (G) Huh7D cells were transfected with the 1.2-mer WT replicon and an E6AP expression plasmid and then infected with HCV as described above for panel A. (H) Levels of extracellular HCV RNA from cells prepared as described above for panel G were measured as described in the legend of Fig. 1B ( n = 3). (I) Huh7D cells were transfected with the 1.2-mer WT replicon and then infected with HCV as described above for panel A. For lanes 4 and 5, cells were treated with 10 μM 5-aza-2′dC, as described in the legend of Fig. 4G . (J) Levels of extracellular HCV RNA from cells prepared as described above for panel I were measured as described in the legend of Fig. 1B ( n = 5). (K) Huh7D cells were transfected with the 1.2-mer WT replicon and a DNMT shRNA plasmid and then infected with HCV as described above for panel A. (L) Levels of extracellular HCV RNA from cells prepared as described above for panel K were measured as described in the legend of Fig. 1B ( n = 5). (M) Huh7D cells were transfected with HA-HBx and an E6AP shRNA plasmid and then infected with HCV as described above for panel A, followed by Western blotting. (N) Levels of extracellular HCV RNA from Huh7D cells prepared as described above for panel M were measured as described in the legend of Fig. 1B ( n = 5). (O) Huh7D cells were transfected with the 1.2-mer WT replicon and E6AP shRNA and then infected with HCV as described above for panel A. (P) Levels of extracellular HCV RNA from cells prepared as described above for panel O were measured as described in the legend of Fig. 1B ( n = 5).

Article Snippet: The E6AP expression plasmid pCMVT N-HA-hE6AP (catalog no. 37601), encoding full-length human HA-tagged E6AP, was purchased from Addgene.

Techniques: Expressing, DNA Methylation Assay, Transfection, Plasmid Preparation, Infection, Western Blot, Quantitative RT-PCR, shRNA